IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2023 | $28.00 | Buy | Guggenheim |
| 1/4/2023 | $27.00 | Outperform | Oppenheimer |
| 6/29/2022 | $18.00 | In-line → Outperform | Evercore ISI |
| 3/25/2022 | $50.00 → $10.00 | Outperform → In-line | Evercore ISI |
| 12/29/2021 | $50.00 | Buy | Jefferies |
| 8/23/2021 | $50.00 | Outperform | Evercore ISI Group |
| 8/23/2021 | $45.70 | Outperform | William Blair |
| 8/23/2021 | Outperform | Cowen & Co. | |
| 8/23/2021 | $50.00 | Buy | Jefferies |
| 8/23/2021 | Outperform | William Blair |
4 - Icosavax, Inc. (0001786255) (Issuer)
4 - Icosavax, Inc. (0001786255) (Issuer)
4 - Icosavax, Inc. (0001786255) (Issuer)
4 - Icosavax, Inc. (0001786255) (Issuer)
4 - Icosavax, Inc. (0001786255) (Issuer)
4 - Icosavax, Inc. (0001786255) (Issuer)
4 - Icosavax, Inc. (0001786255) (Issuer)
4 - Icosavax, Inc. (0001786255) (Issuer)
4 - Icosavax, Inc. (0001786255) (Issuer)
4 - Icosavax, Inc. (0001786255) (Issuer)
- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well tolerated with no vaccine-related SAEs - - Provides initial indication of a differentiated VLP platform technology - - Icosavax plans to file an IND submission and initiate a Phase 1 trial for IVX-A12, a combination bivalent RSV + hMPV VLP candidate, in 2H 2022 – - Company to host conference call/webcast today at 4:30 p.m. ET / 1:30 p.m. PT - SEATTLE, June 28, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP
SC 13D/A - Icosavax, Inc. (0001786255) (Subject)
SC 13D/A - Icosavax, Inc. (0001786255) (Subject)
SC 13G/A - Icosavax, Inc. (0001786255) (Subject)
SC 13G - Icosavax, Inc. (0001786255) (Subject)
SC 13G - Icosavax, Inc. (0001786255) (Subject)
SC 13G - Icosavax, Inc. (0001786255) (Subject)
SC 13G/A - Icosavax, Inc. (0001786255) (Subject)
SC 13G - Icosavax, Inc. (0001786255) (Subject)
SC 13G/A - Icosavax, Inc. (0001786255) (Subject)
SC 13D/A - Icosavax, Inc. (0001786255) (Subject)
15-12G - Icosavax, Inc. (0001786255) (Filer)
SC TO-T/A - Icosavax, Inc. (0001786255) (Subject)
EFFECT - Icosavax, Inc. (0001786255) (Filer)
25-NSE - Icosavax, Inc. (0001786255) (Subject)
S-8 POS - Icosavax, Inc. (0001786255) (Filer)
POS AM - Icosavax, Inc. (0001786255) (Filer)
8-K - Icosavax, Inc. (0001786255) (Filer)
SC 14D9/A - Icosavax, Inc. (0001786255) (Subject)
SC TO-T/A - Icosavax, Inc. (0001786255) (Subject)
SC 14D9/A - Icosavax, Inc. (0001786255) (Subject)
SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today provided a corporate update and shared anticipated milestones for 2022. Pipeline Updates: Exercised option for patent license for influenza vaccine from the University of Washington (UW) and U.S. Department of Human and Health Services (HHS). Icosavax has exercised its option for a non-exclusive patent license granted by UW and HHS for use of its computationally designed, two component VLP platform in the influenza field, as the company executes on its strategy to
SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of John Shiver, Ph.D., to its Board of Directors. Dr. Shiver has more than 30 years of experience in vaccine and pharmaceutical research and development, including at two of the most prominent vaccine companies in the world, Sanofi Pasteur and Merck & Co., Inc. He has guided scientific teams to create novel vaccine and monoclonal antibody candidates to prevent or treat more than 40 infectious and non-infectious diseases, including RSV, infl
SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of Elizabeth Bekiroğlu to General Counsel. "Elizabeth is an accomplished leader who has established an expertise in providing legal counsel to biotechnology and healthcare companies," said Adam Simpson, Chief Executive Officer of Icosavax. "I am thrilled to begin working alongside Elizabeth and look forward to her valuable insight as we work to progress our clinical candidates down the development pipeline and continue to grow the compa
Guggenheim initiated coverage of Icosavax with a rating of Buy and set a new price target of $28.00
Oppenheimer initiated coverage of Icosavax with a rating of Outperform and set a new price target of $27.00
Evercore ISI upgraded Icosavax from In-line to Outperform and set a new price target of $18.00
Evercore ISI downgraded Icosavax from Outperform to In-line and set a new price target of $10.00 from $50.00 previously
Jefferies resumed coverage of Icosavax with a rating of Buy and set a new price target of $50.00
Evercore ISI Group initiated coverage of Icosavax with a rating of Outperform and set a new price target of $50.00
William Blair initiated coverage of Icosavax with a rating of Outperform and set a new price target of $45.70
Cowen & Co. initiated coverage of Icosavax with a rating of Outperform
Jefferies initiated coverage of Icosavax with a rating of Buy and set a new price target of $50.00
William Blair initiated coverage of Icosavax with a rating of Outperform
Simpson has helped build 11 companies that have been acquired or gone public, most recently serving as CEO of Icosavax Frazier Life Sciences (FLS), a longstanding investment firm investing in innovative biopharmaceuticals, today announced the addition of industry veteran Adam Simpson as Venture Partner in its Company Creation team. Over the last 25 years, Simpson has served as a co-founder, executive and/or board member of 11 life sciences companies that have either been acquired or gone public. His broad experience from these roles focuses on team building, advancing novel technologies through clinical proof-of-concept and leading significant fundraising, partnerships and acquisitions. H
PRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON – 19 March 2024 -- CHARM Therapeutics ("CHARM", "The Company"), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine. The newly formed Board is comprised of world-leading experts whose skillsets span 3D deep learning and protein structure prediction, drug discovery and oncology. These individuals have a deep understanding of CHARM and
Building on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ:ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will build on AstraZeneca's expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca's Vaccines & Immune Therapies late-stage pipeline with Icosavax's lead investigational vaccine candidate, IVX-A12. IVX
- Icosavax stockholders to receive $15.00 per share in cash at closing plus non-tradeable contingent value right (CVR) of up to $5.00 per share - - Representing a total equity value of up to $1.1 billion including the CVR - SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX) today announced it has entered into a definitive agreement pursuant to which AstraZeneca, through an acquisition subsidiary, will initiate a tender offer to acquire all of Icosavax's outstanding shares for a price of $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash, payable upon achievement of specified regulatory and net sales mileston
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV, and was generally well tolerated, consistent with prior IVX-A12 Phase 1 data – SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults. "We're
- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023 - - Completed candidate selection for SARS-CoV-2 and influenza programs, highlighting company's antigen design capabilities - - Cash and cash equivalents, and short-term investments of $229.2 million at end 3Q 2023 - SEATTLE, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respirat
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the Jefferies London Healthcare Conference, taking place from November 14-16, 2023 in London, UK. Jefferies London Healthcare Conference Adam Simpson, Chief Executive Officer of Icosavax, will participate in a fireside chat in London on Wednesday, Novem
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference, taking place from November 6-7, 2023 in New York City. Guggenheim's 5th Annual Inflammation, Neurology & Immunology (INI) Conference Adam Simpson, Chief Executi
SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the Cantor Fitzgerald Global Healthcare Conference 2023, taking place from September 26-28, 2023 in New York City. Cantor Fitzgerald Global Healthcare Conference 2023 Adam Simpson, Chief Executive Officer of Icosavax, will participate in a fireside chat in New York City on Tuesday, Se
- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept for revaccination with IVX-121 against RSV - - Initiation of Phase 2 Trial of IVX-A12 with topline interim results now expected by end 2023 - - Closed $67.8 million registered direct offering of common stock; extended cash runway into 2H 2025 - SEATTLE, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ:ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on li